Table 1.
IGF-1R targeted drugs evaluated in human trials
| DRUG | CLASS |
|---|---|
| AMG479 (Ganitumab) | Human monoclonal antibody targeting IGF-1R |
| AVE1642 | Human monoclonal antibody targeting IGF-1R |
| BIIB022 | Human monoclonal antibody targeting IGF-1R |
| CP-751,871 (figitumab) | Human monoclonal antibody targeting IGF-1R |
| IMCA12 (cixutumumab) | Human monoclonal antibody targeting IGF-1R |
| MK7454 (robatumumab) | Human monoclonal antibody targeting IGF-1R |
| MK0646 (dalotuzumab) | Human monoclonal antibody targeting IGF-1R |
| MM141 (istiratumab) | Human monoclonal bispecific antibody targeting IGF-1R and ErbB3 |
| RG1507 (teprotumumab) | Human monoclonal antibody targeting IGF-1R |
| AXL1717 (picropodophyllotoxin) | Small molecule non ATP-competitive IGF-1R kinase inhibitor |
| BMS-754,807 | Small molecule ATP-competitive IGF-1R kinase inhibitor |
| KW-2450 | Small molecule IGF-1R and InsR kinase inhibitor |
| OSI906 (Linsitinib) | Small molecule ATP-competitive IGF-1R and InsR kinase inhibitor |
| PL225B | Small molecule IGF-1R kinase inhibitor |
| XL228 | Multi-targeted small molecule inhibitor of the IGF1R, Src, Abl tyrosine kinases |
| IGV-001 | Biologic-device; patient derived GBM cells treated with an antisense oligodeoxynucleotide towards IGF-1R |